Cardiovascular, kidney and safety outcomes with glp-1 receptor agonists alone and in combination with SGLT2 inhibitors in type 2 diabetes: a systematic review and meta-analysis
Neuen BL, Fletcher RA, Heath L, et al.
Circulation. Pub. online 30 Aug 2024.
Leggi